European Journal of Pharmacology 1991: Vol 209 Index

13 Pages·1991·2.2 MB·English

European Journal of Pharmacology, 209 (1991) 287-289
© 1991 Elsevier Science Publishers B.V. All rights reserved 0014-/2919 /9$039.5 0
Author index
Andersson, S.E. and Le Greves, P. Eglezos, A., Giuliani, S., Viti, G. and Maggi, C.A.
Ruthenium red and capsaicin induce a neurogenic inflammatory Direct evidence that capsaicin-induced plasma protein extravasa-
response in the rabbit eye: effects of w-conotoxin GVIA and tion is mediated through tachykinin NK, receptors (209) 277
tetrodotoxin (209) 175 Emri, Z., see Juhasz, G. (209) 131
Angelucci, F., see Negri, L. (209) 163 Erdé, S.L., see Kiss, B. (209) 109
Arlinghaus, L., Mehdi, S. and Lee, K.S. Eurin, J., see Zongazo, M.A. (209) 45
Improved posthypoxic recovery with a membrane-permeable cal-
pain inhibitor (209) 123 Fekete, 1., see Molnar, L. (209) 81
Asano, T., see Sako, K. (209) 39 Feldman, J., see Tibiriga, E. (209) 213
Ashby, Jr., C.R., see Minabe, Y. (209) 143 Fletcher, P_J., see Kish, S.J. (209) 101
Ashby, Jr., C.R., see Minabe, Y. (209) 151 Fredholm, B.B., see Hu, P.-S. (209) 87
Barrigon, S., see Salinas, P. (209) 105 Gacel, G., see Calenco-Choukroun, G. (209) 267
Barthelemy, C., see Zongazo, M.A. (209) 45 Gale, K., see Meloni, R. (209) 113
Batchelor, A.M., see East, S.J. (209) 119 Garthwaite, J., see East, S.J. (209) 119
Benishin, C., see Hu, P.-S. (209) 87 Gay, N., see Lepetit, P. (209) 207
Bluthé, R.-M., Dantzer, R. and Kelley, K.W. Gemma, C., Ghezzi, P. and De Simoni, M.G.
Interleukin-1 mediates behavioural but not metabolic effects of Activation of the hypothalamic serotoninergic system by central
tumor necrosis factor a in mice (209) 281 interleukin-1 (209) 139
Bobillier, P., see Lepetit, P. (209) 207 Gertner, S.B., see McLeod, R.L. (209) 141
Bousquet, P., see Tibiriga, E. (209) 213 Ghezzi, P., see Gemma, C. (209) 139
Brus, R., see Kostrzewa, R.M. (209) 157 Giuliani, S., see Eglezos, A. (209) 277
Gonon, F., see Tibiriga, E. (209) 213
Grange, E., see Lepetit, P. (209) 207
Cai, N.-s., see Kiss, B. (209) 109
Gui-Hua, C. and Woolverton, W.L.
Calenco-Choukroun, G., Daugé, V., Gacel, G. and Roques, B.P.
Antagonism of quinpirole by (+)-AJ 76: possible involvement of
Lesion of dopamine mesolimbic neurons blocks behavioral effects
D, receptors (209) 285
induced by the endogenous enkephalins but not by a y-opioid
Guillemain, I., see Rollandy, 1. (209) 95
receptor agonist (209) 267
Campbell, B.J., Dimaline, R., Dockray, G.J. and Hughes, J.
Hammer, Jr., R.P., Seatriz, J.V. and Ricalde, A.R
Inhibition of food intake by omeprazole in the chicken (209) 231
Regional dependence of morphine-induced y-opiate receptor
Carayon, A., see Zongazo, M.A. (209) 45
down-regulation in perinatal rat brain (209) 253
Chiba, S., see Iwatsuki, K. (209) 63
Hara, H., Onodera, H., Kawagoe, J.-i. and Kogure, K.
Czachura, J.F., see Rasmussen, K. (209) 135
Failure of basic fibroblast growth factor to prevent postischemic
neuronal damage in the rat (209) 195
Dantzer, R., see Bluthé, R.-M. (209) 281 Harhammer, R., Schafer, U., Henklein, P., Ott, T. and Repke, H.
Darrow, E., Strahlendorf, J.C. and Strahlendorf, H.K. CCK-8-related C-terminal tetrapeptides: affinities for central
Extracellular magnesium concentration alters Purkinje cell re- CCK, and peripheral CCK, receptors (209) 263
sponsiveness to serotonin and analogues (209) 19 Hashimoto, M., Hashimoto, T. and Kuriyama, K.
Daugé, V., see Calenco-Choukroun, G. (209) 267 Protective effect of WEB 1881 FU on AF64A (ethyicholine
De Simoni, M.G., see Gemma, C. (209) 139 aziridinium ion)-induced impairment of hippocampal cholinergic
Dimaline, R., see Campbell, B.J. (209) 231 neurons and learning acquisition (209) 9
Dockray, G.J., see Campbell, B.J. (209) 231 Hashimoto, T., see Hashimoto, M. (209) 9
Drapeau, G., see Rollandy, I. (209) 95 Hegediis, K., see Molnar, L. (209) 81
Dumont, M. and Lemaire, S. Heilig, M., Edvinsson, L. and Wahlestedt, C.
Interaction of 1,3-di(2-(5-*H]tolyl)guanidine with a, binding sites Effects of intracerebroventricular D-myo-inositol-1,2,6-trisphos-
in rat heart membrane preparations (209) 245 phate (PP56), a proposed neuropeptide Y (NPY) antagonist, on
Durieux, C., Ruiz-~Gayo, M. and Roques, B.P. locomotor activity, food intake, central effects of NPY and NPY-
In vivo binding affinities of cholecystokinin agonists and antago- receptor binding (209) 27
nists determined using the selective CCK, agonist (*H]pBC 264 Henklein, P., see Harhammer, R. (209) 263
(209) 185 Hey, J.A., see McLeod, R.L. (209) 141
Hjorth, S. and Tao, R.
East, S.J., Batchelor, A.M. and Garthwaite, J. The putative 5-HT,, receptor agonist CP-93,129 suppresses rat
Selective blockade of N-methyl-D-aspartate receptor function by hippocampal 5-HT release in vivo: comparison with RU 24969
the nitric oxide donor, nitroprusside (209) 119 (209) 249
Edvinsson, L., see Heilig, M. (209) 27 Hofman, G., see Van Oosterhout, A.J.M. (209) 237
288
Horiuchi, A., see Iwatsuki, K. (209) 63 Mabley, J., Wayman, C.P. and Wilson, J.F
Howbert, J.J., see Rasmussen, K. (209) 135 Endogenous y-aminobutyric acid tonically inhibits release of a-
Hu, P.-S., Benishin, C. and Fredholm, B.B. melanocyte-stimulating hormone from rat hypothalamic slices
Comparison of the effects of four dendrotoxin peptides, 4- (209) 127
aminopyridine and tetraethylammonium on the electrically evoked Maggi, C.A., see Eglezos, A. (209) 277
[*H]noradrenaline release from rat hippocampus (209) 87 Maigret, C., see Van Wimersma Greidanus, T.B. (209) 57
Hughes, J., see Campbell, B.J. (209) 231 Maistre, G., see Zongazo, M.A. (209) 45
Masson, F., see Zongazo, M.A. (209) 45
McLeod, R.L., Gertner, S.B. and Hey, J.A.
Imhoff, V., see Rollandy, I. (209) 95 Modulation of cardiovascular function by central histamine H,
Inukai, T., see Shimomura, Y. (209) 15 receptors in conscious guinea pigs (209) 141
Iwatsuki, K., Horiuchi, A., Ren, L.-M. and Chiba, S. Mehdi, S., see Arlinghaus, L. (209) 123
Effects of the cyclic nucleotide phosphodiesterase inhibitors, Meloni, R. and Gale, K.
rolipram, 3-isobutyl-1-methylxanthine, amrinone and zaprinast, Cocaine-induced turning behavior in rats with 6-hydroxydopa-
on pancreatic exocrine secretion in dogs (209) 63 mine lesions: effect of transplants of fetal substantia nigra (209)
113
Memo, M., see Pizzi, M. (209) 169
Juhasz, G., Kékesi, K.A., Emri, Z., Ujszaszi, J., Krogsgaard—Larsen, Mermet, C., see Tibiriga, E. (209) 213
P. and Schousboe, A.
Minabe, Y., Ashby, Jr., C.R. and Wang, R.Y.
Sleep promoting effect of a putative glial y-aminobutyric acid
The effect of acute and chronic LY 277359, a selective 5-HT,
uptake blocker applied in the thalamus of cats (209) 131
receptor antagonist, on the number of spontaneously active mid-
brain dopamine neurons (209) 151
Minabe, Y., Ashby, Jr., C.R., Schwartz, J.E. and Wang, R.Y
Kalbfleisch, J., see Kostrzewa, R.M. (209) 157
The 5-HT, receptor antagonists LY 277359 and granisetron po-
Kauffman, G., see Saperas, E. (209) 1
tentiate the suppressant action of apomorphine on the basal
Kawagoe, J.-i., see Hara, H. (209) 195
firing rate of ventral tegmental dopamine cells (209) 143
Kékesi, K.A., see Juhasz, G. (209) 131
Molenaar, P., Roberts, S.J., Kim, Y.S., Pak, H.S., Sainz, R.D. and
Kelley, K.W., see Bluthé, R.-M. (209) 281
Summers, R.J.
Kikuchi de Beltran, K., see Koshikawa, N. (209) 75
Localization and characterization of two propranolol resistant
Kim, Y.S., see Molenaar, P. (209) 257
(- \'*>Icyanopindolol binding sites in rat skeletal muscle (209)
Kish, S.J., Wilson, J.M. and Fletcher, PJ.
257
The polyamine synthesis inhibitor a-difluoromethylornithine is
Molnar, L., Hegediis, K. and Fekete, |
neuroprotective against N-methyl-D-aspartate-induced brain
Difference between the cerebrovascular effect of purinergic Co-
damage in vivo (209) 101
ATP and that of the cholinesterase inhibitor, physostigmine, in
Kiss, B., Cai, N.-s. and Erdé, S.L.
vivo (209) 81
Vinpocetine preferentially antagonizes quisqualate/AMPA re-
Monassier, L., see Tibiriga, E. (209) 213
ceptor responses: evidence from release and ligand binding stud-
ies (209) 109
Klee, A., Schmid-Schénbein, G.W. and Seiffge, D.
Negri, L., Noviello, V. and Angelucci, F.
Effects of platelet activating factor on rat platelets in vivo (209)
Behavioural effects of deltorphins in rats (209) 163
223
Nielsen-Kudsk, J.E. and Thirstrup, S.
Kobayashi, I., see Shimomura, Y. (209) 15
Antidiabetic sulfonylureas relax isolated rabbit coronary arteries
Kobayashi, M., see Koshikawa, N. (209) 75
(209) 273
Kobayashi, S., see Shimomura, Y. (209) 15
Nijkamp, F.P., see Van Oosterhout, A.J.M. (209) 237
Koekkoek-Van den Herik, 1., see Van de Heijning, B.J.M. (209) 199
Noé, E., see Zongazo, M.A. (209) 45
Kogure, K., see Hara, H. (209) 195
Noviello, V., see Negri, L. (209) 163
Komajda, M., see Zongazo, M.A. (209) 45
Koshikawa, N., Kikuchi de Beltran, K., Saigusa, T., Kobayashi, M.
and Stephenson, J.D. Onodera, H., see Hara, H. (209) 195
Cholecystokinin octapeptide and caerulein injection into the dor- Ott, T., see Harhammer, R. (209) 263
somedial nucleus accumbens potentiate apomorphine-induced jaw
movements in rats (209) 75
Kostrzewa, R.M., Brus, R. and Kalbfleisch, J Pak, H.S., see Molenaar, P. (209) 257
Ontogenetic homologous sensitization to the antinociceptive ac- Pizzi, M., Ribola, M., Valerio, A., Memo, M. and Spano, P.F.
tion of quinpirole in rats (209) 157 Various Ca** entry blockers prevent glutamate-induced neuro-
Krogsgaard—Larsen, P., see Juhasz, G. (209) 131 toxicity (209) 169
Kuriyama, K., see Hashimoto, M. (209) 9
Kuwabara, A., see Shimomura, Y. (209) 15
Rasmussen, K., Stockton, M.E., Czachura, J.F. and Howbert, J.J.
Cholecystokinin (CCK) and schizophrenia: the selective CCK,
Lee, K.S., see Arlinghaus, L. (209) 123 antagonist LY262691 decreases midbrain dopamine unit activity
Legrand, J.C., see Zongazo, M.A. (209) 45 (209) 135
Le Greves, P., see Andersson, S.E. (209) 175 Regoli, D., see Rollandy, I. (209) 95
Lemaire, S., see Dumont, M. (209) 245 Ren, L.-M., see Iwatsuki, K. (209) 63
Lepetit, P., Touret, M., Grange, E., Gay, N. and Bobillier, P Repke, H., see Harhammer, R. (209) 263
Inhibition of methionine incorporation into brain proteins after Ribola, M., see Pizzi, M. (209) 169
the systemic administration of p-chlorophenylalanine and L-5-hy- Ricalde, A.R., see Hammer, Jr., R.P. (209) 253
droxytryptophan (209) 207 Roberts, S.J., see Molenaar, P. (209) 257
Reed, A. Tanaka, S., see Shikada, K.-i. (209) 69
Separate sites for the dantrolene-induced inhibition of contrac- Tao, R., see Hjorth, S. (209) 249
ture of the rat diaphragm preparation due to depolarization or to Thirstrup, S., see Nielsen-Kudsk, J.E. (209) 273
caffeine (209) 33 Tibiriga, E., Feldman, J., Mermet, C., Monassier, L., Gonon, F. and
Rollandy, 1., Guillemain, 1., Imhoff, V., Drapeau, G., Regoli, D. and Bousquet, P
Rossignol, B. Selectivity of rilmenidine for the nucleus reticularis lateralis, a
Involvement of NK, receptors and importance of the N-terminal ventrolateral medullary structure containing imidazoline-prefer
sequence of substance P in the stimulation of protein secretion in ring receptors (209) 213
rat parotid glands (209) 95 Touret, M., see Lepetit, P. (209) 207
Roques, B.P., see Calenco-Choukroun, G. (209) 267 Tsuchiya, M., see Sako, K. (209) 39
Roques, B.P., see Durieux, C. (209) 185
Rossignol, B., see Rollandy, 1. (209) 95 Uehara, Y., see Shimomura, Y. (209) 15
Ruiz-Gayo, M., see Durieux, C. (209) 185 Ujszaszi, J., see Juhasz, G. (209) 131
Saigusa, T., see Koshikawa, N. (209) 75
Valerio, A., see Pizzi, M. (209) 169
Sainz, R.D., see Molenaar, P. (209) 257
Van de Heijning, BJ.M., Koekkoek-Van den Herik, I. and
Sako, K., Tsuchiya, M., Yonemasu, Y. and Asano, T
Van Wimersma Greidanus, T.B
HA1077, a novel calcium antagonistic antivasospasm drug, in-
The opioid receptor subtypes uw and «x, but not 4, are involved in
creases both cerebral blood flow and glucose metabolism in
the control of the vasopressin and oxytocin release in the rat
conscious rats (209) 39
(209) 199
Salinas, P. and Barrigon, S
Van Oosterhout, A.J.M., Hofman, G., Woutersen-Van Nijnanten,
Protective effects of dazmegrel on the PAF potential of ouabain-
F.M.A. and Nijkamp, F.P
induced cardiac arrhythmias (209) 105
5-HT,-like receptors mediate potentiation of cholinergic nerve-
Saperas, E., Kauffman, G. and Taché, Y
mediated contraction of isolated mouse trachea (209) 237
Role of central prostaglandin E, in the regulation of gastric acid
Van Wimersma Greidanus, T.B. and Maigret, C
secretion in the rat (209) |
Neuromedin-induced excessive grooming / scratching behavior is
Sato, N., see Shimomura, Y. (209) 15
suppressed by naloxone, neurotensin and a dopamine D, recep-
Schafer, U., see Harhammer, R. (209) 263
tor antagonist (209) 57
Schmid-Schénbein, G.W., see Klee, A. (209) 223
Van Wimersma Greidanus, T.B., see Van de Heijning, B.J.M. (209)
Schousboe, A., see Juhasz, G. (209) 131
199
Schwartz, J.E., see Minabe, Y. (209) 143
Viti, G., see Eglezos, A. (209) 277
Seatriz, J.V., see Hammer, Jr., R.P. (209) 253
Seiffge, D., see Klee, A. (209) 223
Wahlestedt, C., see Heilig, M. (209) 27
Shikada, K.-i., Yamamoto, A. and Tanaka, S.
Wang, R.Y., see Minabe, Y. (209) 143
NIP-121 and cromakalim, potassium channel openers, preferen-
Wang, R.Y., see Minabe, Y. (209) 151
tially suppress prostanoid-induced contraction of the guinea-pig
Wayman, C.P., see Mabley, J. (209) 127
isolated trachea (209) 69
Wilson, J.F., see Mabley, J. (209) 127
Shimizu, H., see Shimomura, Y. (209) 15
Wilson, J.M., see Kish, S.J. (209) 101
Shimomura, Y., Inukai, T., Kuwabara, A., Shimizu, H., Sato, N.,
Woolverton, W.L., see Gui-Hua, C. (209) 285
Uehara, Y., Kobayashi, I. and Kobayashi, S
Woutersen-Van Nijnanten, F.M.A., see Van Oosterhout, AJ.M
Enhanced sensitivity to anorexia and consumption of drinking
(209) 237
water induced by interleukin-18 in obese yellow mice (209) 15
Spano, P.F., see Pizzi, M. (209) 169
Stephenson, J.D., see Koshikawa, N. (209) 75 Yamamoto, A., see Shikada, K.-i. (209) 69
Stockton, M.E., see Rasmussen, K. (209) 135 Yonemasu, Y., see Sako, K. (209) 39
Strahlendorf, H.K., see Darrow, E. (209) 19
Strahlendorf, J.C., see Darrow, E. (209) 19 Zongazo, M.A., Carayon, A., Masson, F., Maistre, G., Noé, E.,
Summers, R.J., see Molenaar, P. (209) 257 Eurin, J., Barthelemy, C., Komajda, M. and Legrand, J.C
Effects of arginine vasopressin and extracellular osmolarity on
Taché, Y., see Saperas, E. (209) 1 atrial natriuretic peptide release by superfused rat atria (209) 45

European Journal of Pharmacology, 209 (1991) 291-298
© 1991 Elsevier Science Publishers B.V. All rights reserved 0014-2999 /91 /$03.50
Key word index
Acetylcholine Apomorphine
WEB 1881 FU; Hippocampus; AF64A; Memory (Hashimoto, M CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Jaw
(209) 9) movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209)
75)
Acetylcholine release
Vinpocetine; Excitatory amino acid receptors; Dopamine release; Appetitive behaviour
NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA bind- Interleukin-18; Ibuprofen; (Yellow mice) (Shimomura, Y. (209) 15)
ing (Kiss, B. (209) 109)
ATP
a@ ,-Adrenoceptors Physostigmine; Cerebral vasodilatation; (Mode of action), (Rabbit)
Transmitter release: K* channels; Aminopyridines; Tetraethylam- (Molnar, L. (209) 81)
monium (Hu, P.-S. (209) 87)
Atrium (rat)
B-Adrenoceptors (atypical) ANP release; Ca** influence; V, receptor antagonists; Osmolarity
Skeletal muscle; (—)-('*I]cyanopindolol; BRL 37344; Alprenolol; (Zongazo, M.A. (209) 45)
5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)
Autoradiography (quantitative)
AF64A p-Chlorophenylalanine; L-5-Hydroxytryptophan; 5-HT (5-hydroxy
WEB 1881 FU; Hippocampus; Acetylcholine; Memory (Hashimoto, tryptamine, serotonin), Brain protein synthesis (Lepetit, P. (209) 207)
M. (209) 9)
Azepexole
Alprenolol Rilmenidine; Clonidine; Voltammetry (in vivo); Blood pressure; Imi-
B-Adrenoceptors (atypical); Skeletal muscle; (—)-{'?>I}cyanopindo- dazoline-preferring receptors (Tibirica, E. (209) 213)
lol; BRL 37344; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar,
P. (209) 257) Baclofen
Prostaglandin E,; Indomethacin; Gastric acid secretion; Vagus
Aminopyridines (Saperas, E. (209) 1)
Transmitter release: K* channels; Tetraethylammonium: a,-Adren-
oceptors (Hu, P.-S. (209) 87) Basal ganglia
Dopamine uptake; Striatum; Postural asymmetry; Nomifensine; GBR
AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-propionic acid) 12909; Amphetamine (Meloni, R. (209) 113)
Glutamate; Ca** entry blockers; Neurotoxicity (Pizzi, M. (209) 169)
Benzodiazepines
AMPA binding a-MSH (a-melanocyte-stimulating hormone); GABA (y-aminobu-
Vinpocetine; Excitatory amino acid receptors; Dopamine release; tyric acid); Hypothalamus (Mabley, J. (209) 127)
Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate;
Kainate (Kiss, B. (209) 109) Binding in vivo
CCK-8 (cholecystokinin octapeptide); CCK, receptors; Peptidase
Amphetamine inhibitors, CCK receptor agonists; CCK receptor antagonists;
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia; [*H]pBC 264; (Mouse) (Durieux, C. (209) 185)
Nomifensine; GBR 12909 (Meloni, R. (209) 113)
Blood-aqueous barrier
Analgesia CGRP (calcitonin gene-related peptide); Capsaicin; Miosis; Ruthe-
Deltorphins; 5-Opioid receptors; Locomotor activity; Social be- nium red; Substance P (Andersson, S.E. (209) 175)
haviour; (Rat) (Negri, L. (209) 163)
Blood pressure
ANP release Rilmenidine; Azepexole; Clonidine; Voltammetry (in vivo), Imidazo-
Atrium (rat); Ca** influence; V, receptor antagonists; Osmolarity line-preferring receptors (Tibirica, E. (209) 213)
(Zongazo, M.A. (209) 45)
Body weight
Antinociception Tumor necrosis factor; Interleukin-1; Interleukin-1 receptor antago-
Quinpirole; Dopamine; Receptor sensitization (Kostrzewa, R.M nists; Social behaviour; (Mouse) (Bluthé, R.-M. (209) 281)
(209) 157)
Brain protein synthesis
Antipsychotic drugs p-Chlorophenylalanine; L-5-Hydroxytryptophan; 5-HT (5-hydroxy-
Cholecystokinin (CCK); CCK, receptors; Schizophrenia; Dopamine tryptamine, serotonin); Autoradiography (quantitative) (Lepetit, P
neurons; LY262691 (Rasmussen, K. (209) 135) (209) 207)
292
Brain (rat) CCK-8 (cholecystokinin octapeptide); Tetrapeptides; (Radioligand
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); binding) (Harhammer, R. (209) 263)
5-HT,, receptor agonists; RU 24969 (S-methoxy-3-(1,2,5,6-tetrahy-
dropyridyl)indole); Methiothepin; 5-HT release (in vivo); Microdialy- Cerebellum
sis (Hjorth, S. (209) 249) NMDA receptors; Nitroprusside; Nitric oxide (NO); cGMP (East,
S.J. (209) 119)
BRL 37344
B-Adrenoceptors (atypical); Skeletal muscle; (—)-{'**I}cyanopindo- Cerebral blood flow
lol; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. Cerebral glucose metabolism; lodoantipyrine; 2-Deoxyglucose;
(209) 257) HA1077 (Sako, K. (209) 39)
Ca** entry blockers Cerebral glucose metabolism
Glutamate; AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-pro- Cerebral blood flow; lodoantipyrine; 2-Deoxyglucose; HA1077 (Sako,
pionic acid); Neurotoxicity (Pizzi, M. (209) 169) K. (209) 39)
Cerebral ischemia
Caerulein
bFGF (basic fibroblast growth factor); Hippocampus; Vulnerability
CCK-8 (cholecystokinin octapeptide); Lorglumide; Apomorphine;
(selective); (Rat) (Hara, H. (209) 195)
Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N.
(209) 75)
Cerebral vasodilatation
ATP; Physostigmine; (Mode of action); (Rabbit) (Molnar, L. (209)
Caffeine contracture
81)
Dantrolene; Depolarization contractures; Diaphragm (rat) (Red, A.
(209) 33)
CGRP (calcitonin gene-related peptide)
Blood-aqueous barrier; Capsaicin; Miosis; Ruthenium red; Sub-
Ca** influence
stance P (Andersson, S.E. (209) 175)
Atrium (rat); ANP release; V, receptor antagonists; Osmolarity
(Zongazo, M.A. (209) 45)
p-Chlorophenylalanine
L-5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin);
Calpain inhibitor Brain protein synthesis; Autoradiography (quantitative) (Lepetit, P
Neuroprotection; Hypoxia; Hippocampal slice; Proteolysis; (Rat) (209) 207)
(Arlinghaus, L. (209) 123)
Cholecystokinin (CCK)
Capsaicin CCK , receptors; Schizophrenia; Dopamine neurons; LY262691; An-
Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); tipsychotic drugs (Rasmussen, K. (209) 135)
Miosis; Ruthenium red; Substance P (Andersson, S.E. (209) 175)
Clonidine
CCK-8 (cholecystokinin octapeptide) Rilmenidine; Azepexole; Voltammetry (in vivo); Blood pressure;
Caerulein; Lorglumide; Apomorphine; Jaw movements; Dorsomedial Imidazoline-preferring receptors (Tibiriga, E. (209) 213)
nucleus accumbens (Koshikawa, N. (209) 75)
Coronary aretery
CCK, receptors; Binding in vivo; Peptidase inhibitors; CCK recep- Sulfonylureas; Glibenclamide; Cromakalim; K* channels; Smooth
tor agonists; CCK receptor antagonists; [*H]pBC 264; (Mouse) muscle (Nielsen-Kudsk, J.E. (209) 273)
(Durieux, C. (209) 185)
(+)-CP-96,345
Plasma protein extravasation; Neurogenic inflammation; Tachykinin
CCK, receptors; Tetrapeptides; (Radioligand binding) (Harhammer,
NK, receptors (Eglezos, A. (209) 277)
R. (209) 263)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl) pyrrolo[3,2-b] pyrid-5-one)
CCK receptor agonists
5-HT\, receptor agonists; RU 24969 (S-methoxy-3-(1,2,5,6-tetrahy-
CCK-8 (cholecystokinin octapeptide); CCK, receptors; Binding in
dropyridyl indole); Methiothepin; 5-HT release (in vivo); Microdialy-
vivo; Peptidase inhibitors; CCK receptor antagonists; [*H]pBC 264;
sis; Brain (rat) (Hjorth, S. (209) 249)
(Mouse) (Durieux, C. (209) 185)
Cromakalim
CCK receptor antagonists K* channel opener; NIP-121; Glibenclamide; Prostaglandin; Tra-
CCK-8 (cholecystokinin octapeptide); CCK, receptors; Binding in chea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)
vivo; Peptidase inhibitors; CCK receptor agonists; [*H]pBC 264;
(Mouse) (Durieux, C. (209) 185)
Sulfonylureas; Glibenclamide; K* channels; Coronary aretery;
Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)
CCK, receptors
Cholecystokinin (CCK); Schizophrenia; Dopamine neurons; (—)-['**Icyanopindolol
LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135) B-Adrenoceptors (atypical); Skeletal muscle; BRL 37344; Alprenolol;
5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)
CCK-8 (cholecystokinin octapeptide); Binding in vivo; Peptidase
inhibitors; CCK receptor agonists; CCK receptor antagonists; [*H]DAGO binding
[SH]pBC 264; (Mouse) (Durieux, C. (209) 185) Opiates; Development; Hypothalamus (Hammer, Jr., R.P. (209) 253)
DALDA (H-Tyr-D-Arg-Phe-Lys-NH ,) Dorsomedial nucleus accumbens
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Apo-
Naltrindole; DPDPE ((D-Pen?,D-Pen* Jenkephalin); U-69,593 (Van morphine; Jaw movements (Koshikawa, N. (209) 75)
de Heijning, B.J.M. (209) 199)
DPDPE ((D-Pen?,D-Pen* Jenkephalin)
Dantrolene Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI);
Depolarization contractures; Caffeine contracture; Diaphragm (rat) Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH,); U-69,593
(Reed, A. (209) 33) (Van de Heijning, B.J.M. (209) 199)
Dazmegrel DTG (1,3-di(2-tolyl) guanidine)
PAF (platelet-activating factor, PAF-acether); Lysine-acetylsalicy- o@ Receptors; Phencyclidine (PCP); SK&F 10047 (Dumont, M. (209)
late; Ouabain-induced arrhythmia; (Guinea-pig) (Salinas, P. (209) 245)
105)
Electrical field stimulation
Deltorphins 5-HT (S-hydroxytryptamine, serotonin); Trachea; Respiratory airways
5-Opioid receptors; Locomotor activity; Social behaviour; Analgesia; (Van Oosterhout, A.J.M. (209) 237)
(Rat) (Negri, L. (209) 163)
Excitatory amino acid receptors
Vinpocetine; Dopamine release; Acetylcholine release; NMDA (N-
2-Deoxyglucose
methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B
Cerebral blood flow; Cerebral glucose metabolism; lodoantipyrine;
HA1077 (Sako, K. (209) 39) (209) 109)
Exocrine secretion
Depolarization contractures
Pancreas (dog); Phosphodiesterase inhibitors; Rolipram (Iwatsuki, K
Dantrolene; Caffeine contracture; Diaphragm (rat) (R@ed, A. (209)
(209) 63)
33)
bFGF (basic fibroblast growth factor)
Desensitization Cerebral ischemia; Hippocampus; Vulnerability (selective), (Rat)
PAF-specific; Pulmonary platelet accumulation; (Rat) (Kiee, A. (209) (Hara, H. (209) 195)
223)
Food intake
Development Omeprazole; Gastrin; (Chicken) (Campbell, B.J. (209) 231)
Opiates; [SH]DAGO binding; Hypothalamus (Hammer,Jr ., R.P
(209) 253) GABA (y-aminobutyric acid)
a-MSH (a-melanocyte-stimulating hormone), Benzodiazepines; Hy-
Diaphragm (rat) pothalamus (Mabley, J. (209) 127)
Dantrolene; Depolarization contractures; Ca*icine contracture
(Reed, A. (209) 33) Glial uptake; Thalamus; Sleep; (Cat) (Juhadsz, G. (209) 131)
a -Difluoromethylornithine Gastric acid secretion
Polyamine; NMDA (N-methyl-D-aspartate); Neurotoxicity; Or- Prostaglandin E,; Indomethacin; Vagus; Baclofen (Saperas, E. (209)
nithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101) 1)
Dopamine Gastrin
Antinociception; Quinpirole; Receptor sensitization (Kostrzewa, Omeprazole; Food intake; (Chicken) (Campbell, B.J. (209) 231)
R.M. (209) 157)
GBR 12909
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia;
Dopamine cells
Nomifensine; Amphetamine (Meloni, R. (209) 113)
5-HT, receptor antagonists; LY 277359; Granisetron; Ventral
tegmental area (Minabe, Y. (209) 143)
Glial uptake
GABA (y-aminobutyric acid); Thalamus; Sleep; (Cat) (Juhasz, G.
Dopamine neurons
(209) 131)
Cholecystokinin (CCK), CCK, receptors; Schizophrenia; LY262691;
Antipsychotic drugs (Rasmussen, K. (209) 135)
Glibenclamide
K* channel opener; NIP-121; Cromakalim; Prostaglandin; Trachea
5-HT, receptors; 5-HT, receptor antagonists; LY 277359; Ventral (isolated, guinea-pig) (Shikada, K.-i. (209) 69)
tegmental area; Substantia nigra pars compacta (Minabe, Y. (209)
151) Sulfonylureas; Cromakalim; K* channels; Coronary aretery; Smooth
muscle (Nielsen-Kudsk, J.E. (209) 273)
Dopamine release
Vinpocetine; Excitatory amino acid receptors; Acetylcholine release; Glutamate
NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA bind- AMPA (2-amino-3-3-hydroxy-5-methylisoxazolyl)-propionic acid);
ing (Kiss, B. (209) 109) Ca** entry blockers; Neurotoxicity (Pizzi, M. (209) 169)
Dopamine uptake cGMP
Striatum; Postural asymmetry; Basal ganglia; Nomifensine; GBR Cerebellum; NMDA receptors; Nitroprusside; Nitric oxide (NO)
12909; Amphetamine (Meloni, R. (209) 113) (East, S.J. (209) 119)
294
Granisetron 6-Hydroxydopamine (6-OHDA)
5-HT, receptor antagonists; LY 277359; Ventral tegmental area; pu-Opioid receptor agonists (selective); 5-Opioid receptor agonists
Dopamine cells (Minabe, Y. (209) 143) (selective); Kelatorphan; Ventral tegmental area; Nucleus accum-
bens; Locomotor activity (Calenco-Choukroun, G. (209) 267)
Grooming / scratching behaviour
Neuromedin B; Neuromedin C (Van Wimersma Greidanus, T.B. L-5-Hydroxytryptophan
(209) 57) p-Chlorophenylalanine; 5-HT (5-hydroxytryptamine, serotonin);
Brain protein synthesis; Autoradiography (quantitative) (Lepetit, P.
HA1077 (209) 207)
Cerebral blood flew; Cerebral glucose metabolism; lodoantipyrine;
2-Deoxyglucose (Sako, K. (209) 39) Hypothalamus
a-MSH (a-melanocyte-stimulating hormone); GABA (y-aminobu-
Hippocampal slice tyric acid); Benzodiazepines (Mabley, J. (209) 127)
Neuroprotection; Calpain inhibitor; Hypoxia; Proteolysis; (Rat)
(Arlinghaus, L. (209) 123) Opiates; [7>HJDAGO binding; Development (Hammer, Jr., R.P. (209)
253)
Hippocampus
WEB 1881 FU; Acetylcholine; AF64A; Memory (Hashimoto, M. Hypoxia
(209) 9) Neuroprotection; Calpain inhibitor; Hippocampal slice; Proteolysis;
(Rat) (Arlinghaus, L. (209) 123)
bFGF (basic fibroblast growth factor); Cerebral ischemia; Vulnera-
bility (selective); (Rat) (Hara, H. (209) 195) Ibuprofen
Interleukin-18; Appetitive behaviour; (Yellow mice) (Shimomura, Y.
5-HT (5-hydroxytryptamine, serotonin) (209) 15)
Purkinje neurons; Microiontophoresis; 5-HT,, receptors; Mg?*; 8-
OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (triflu-
Imidazoline-preferring receptors
oromethylphenylpiperazine) (Darrow, E. (209) 19)
Rilmenidine; Azepexole; Clonidine; Voltammetry (in vivo); Blood
pressure (Tibiriga, E. (209) 213)
p-Chlorophenylalanine; L-5-Hydroxytryptophan; Brain protein syn-
thesis; Autoradiography (quantitative) (Lepetit, P. (209) 207)
Indomethacin
Prostaglandin E,; Gastric acid secretion; Vagus; Baclofen (Saperas,
Electrical field stimulation; Trachea; Respiratory airways (Van Oos-
E. (209) 1)
terhout, A.J.M. (209) 237)
Interleukin-1
B-Adrenoceptors (atypical); Skeletal muscle; (—)-{!7>I]Jcyanopindo-
Tumor necrosis factor; Interleukin-1 receptor antagonists; Social
lol; BRL 37344; Alprenolol (Molenaar, P. (209) 257)
behaviour; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)
5-HT,, receptor agonists
Interleukin-18
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one);
Appetitive behaviour; Ibuprofen; (Yellow mice) (Shimomura, Y
RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methio-
(209) 15)
thepin; 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S.
(209) 249)
Interleukin-1 receptor antagonists
Tumor necrosis factor; Interleukin-1; Social behaviour; Body weight;
5-HT, receptor antagonists
(Mouse) (Bluthé, R.-M. (209) 281)
LY 277359; Granisetron; Ventral tegmental area; Dopamine cells
(Minabe, Y. (209) 143)
lodoantipyrine
Dopamine neurons; 5-HT, receptors; LY 277359; Ventral tegmental Cerebral blood flow; Cerebral glucose metabolism; 2-Deoxyglucose;
area; Substantia nigra pars compacta (Minabe, Y. (209) 151) HA1077 (Sako, K. (209) 39)
IP,
5-HT,, receptors
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, Neuropeptide Y (NPY); Locomotion; (Feeding); (Receptors) (Heilig,
serotonin); Mg?*; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)te- M. (209) 27)
tralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209)
19) Jaw movements
CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Apo-
5-HT, receptors morphine; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)
Dopamine neurons; 5-HT, receptor antagonists; LY 277359; Ventral
tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) Kainate
151) Vinpocetine; Excitatory amino acid receptors; Dopamine release;
Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate;
5-HT release (in vivo) AMPA binding (Kiss, B. (209) 109)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one);
5-HT,g receptor agonists; RU 24969 (S-methoxy-3-(1,2,5,6-tetrahy- K* channel opener
dropyridyl)indole); Methiothepin; Microdialysis; Brain (rat) (Hjorth, NIP-121; Cromakalim; Glibenclamide; Prostaglandin; Trachea (iso-
S. (209) 249) lated, guinea-pig) (Shikada, K.-i. (209) 69)
K* channels Microiontophoresis
Sulfonylureas; Glibenclamide; Cromakalim; Coronary aretery; Purkinje neurons; 5-HT (S-hydroxytryptamine, serotonin); 5-HT,,
Smooth muscle (Nielsen-Kudsk, J.E. (209) 273) receptors; Mg?*; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)}tetra-
lin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)
Kelatorphan
u-Opioid receptor agonists (selective); 5-Opioid receptor agonists Miosis
(selective); 6-Hydroxydopamine (6-OHDA),; Ventral tegmental area; Blood-aqueous barrier; CGRP (calcitonin gene-related peptide),
Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. Capsaicin; Ruthenium red; Substance P (Andersson, S.E. (209) 175)
(209) 267)
a-MSH (a-mel yte-stimulating hormone)
Locomotion GABA (y-aminobutyric acid); Benzodiazepines; Hypothalamus
Neuropeptide Y (NPY); IP,; (Feeding); (Receptors) (Heilig, M. (209) (Mabley, J. (209) 127)
27)
Naloxone
Locomotor activity Vasopressin; Oxytocin; Norbinaltorphimine (norBNI); Naltrindole;
Deltorphins; 5-Opioid receptors; Social behaviour; Analgesia; (Rat) DALDA (H-Tyr-D-Arg-Phe-Lys-NH,); DPDPE ({(D-Pen’,D-
(Negri, L. (209) 163) Pen*J enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)
p-Opioid receptor agonists (selective); 5-Opioid receptor agonists Naltrindole
(selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI);
tegmental area; Nucleus accumbens (Calenco-Choukroun, G. (209) DALDA (H-Tyr-D-Arg-Phe-Lys-NH,); DPDPE ({D-Pen’,D-
267) Pen jenkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)
Lorglumide Neurogenic inflammation
CCK-8 (cholecystokinin octapeptide); Caerulein; Apomorphine; Jaw (+)-CP-96,345; Plasma protein extravasation; Tachykinin NK, re-
movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) ceptors (Eglezos, A. (209) 277)
75)
Neuromedin B
LY262691 Neuromedin C; Grooming/scratching behaviour (Van Wimersma
Cholecystokinin (CCK); CCK, receptors; Schizophrenia; Dopamine Greidanus, T.B. (209) 57)
neurons; Antipsychotic drugs (Rasmussen, K. (209) 135)
Neuromedin C
LY 277359 Neuromedin B; Grooming/scratching behaviour (Van Wimersma
5-HT, receptor antagonists; Granisetron; Ventral tegmental area; Greidanus, T.B. (209) 57)
Dopamine cells (Minabe, Y. (209) 143)
Neuropeptide Y (NPY)
Dopamine neurons; 5-HT, receptors; 5-HT, receptor antagonists; IP,; Locomotion; (Feeding); (Receptors) (Heilig, M. (209) 27)
Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y.
(209) 151)
Neuroprotection
Polyamine; NMDA (N-methyl-D-aspartate), Neurotoxicity; a-Dif-
Lysine-acetylsalicylate
luoromethylornithine; Ornithine decarboxylase (Kish, S.J. (209) 101)
Dazmegrel; PAF (platelet-activating factor, PAF-acether); Ouabain-
induced arrhythmia; (Guinea-pig) (Salinas, P. (209) 105)
Calpain inhibitor; Hypoxia; Hippocampal slice; Proteolysis; (Rat)
(Arlinghaus, L. (209) 123)
Memory
WEB 1881 FU; Hippocampus; Acetylcholine; AF64A (Hashimoto,
Neurotoxicity
M. (209) 9)
Polyamine; NMDA (N-methyl-D-aspartate); a-Difluoromethyl-
ornithine; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209)
Methiothepin
101)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b}pyrid-5-one);
5-HT,, receptor agonists; RU 24969 (S-methoxy-3-(1,2,5,6-tetrahy-
dropyridyl)indole); 5-HT release (in vivo); Microdialysis; Brain (rat) Glutamate; AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-pro-
(Hjorth, S. (209) 249) pionic acid); Ca** entry blockers (Pizzi, M. (209) 169)
Mg?* NIP-121
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, K* channel opener; Cromakalim; Glibenclamide; Prostaglandin;
serotonin); 5-HT,, receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-pro- Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)
pylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Dar-
row, E. (209) 19) Nitric oxide (NO)
Cerebellum; NMDA receptors; Nitroprusside; cGMP (East, S.J. (209)
Microdialysis 119)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b}pyrid-5-one),
5-HT,p, receptor agonists; RU 24969 (S-methoxy-3-(1,2,5,6-tetrahy- Nitroprusside
dropyridyl)indole); Methiothepin; 5-HT release (in vivo); Brain (rat) Cerebellum; NMDA receptors; Nitric oxide (NO), cGMP (East, S.J.
(Hjorth, S. (209) 249) (209) 119)
296
NMDA (N-methyl-D-aspartate) QOuabain-induced arrhythmia
Polyamine; Neurotoxicity; a-Difluoromethylornithine; Ornithine de- Dazmegrel; PAF (platelet-activating factor, PAF-acether); Lysine-
carboxylase; Neuroprotection (Kish, S.J. (209) 101) acetylsalicylate; (Guinea-pig) (Salinas, P. (209) 105)
Vinpocetine; Excitatory amino acid receptors; Dopamine release; Oxytocin
Acetylcholine release; Quisqualate; Kainate; AMPA binding (Kiss, Vasopressin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole;
B. (209) 109) DALDA (H-Tyr-D-Arg-Phe-Lys-NH,); DPDPE ({D-Pen?,D-
Pen* Jenkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)
NMDA receptors
Cerebellum; Nitroprusside; Nitric oxide (NO); cGMP (East, SJ. PAF (platelet-activating factor, PAF-acether)
(209) 119) Dazmegrel; Lysine-acetylsalicylate; Ouabain-induced arrhythmia;
(Guinea-pig) (Salinas, P. (209) 105)
Nomifensine
PAF-specific
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia; GBR
Pulmonary platelet accumulation; Desensitization; (Rat) (Klee, A.
12909; Amphetamine (Meloni, R. (209) 113)
(209) 223)
Norbinaltorphimine (norBNI)
Pancreas (dog)
Vasopressin; Oxytocin; Naloxone; Naltrindole; DALDA (H-Tyr-D-
Exocrine secretion; Phosphodiesterase inhibitors; Rolipram
Arg-Phe-Lys-NH,) ;D PDPE ((D-Pen?,D-Pen* Jenkephalin); U-69,593
(Iwatsuki, K. (209) 63)
(Van de Heijning, B.J.M. (209) 199)
Parotid glands
N-terminal part Tachykinins; Protein secretion; Substance P; N-terminal part (Rol-
Tachykinins; Protein secretion; Substance P; Parotid glands (Rol- landy, I. (209) 95)
landy, I. (209) 95)
[*H)pBC 264
Nucleus accumbens CCK-8 (cholecystokinin octapeptide); CCK, receptors; Binding in
p-Opioid receptor agonists (selective); 5-Opioid receptor agonists vivo; Peptidase inhibitors; CCK receptor agonists; CCK receptor
(selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral antagonists; (Mouse) (Durieux, C. (209) 185)
tegmental area; Locomotor activity (Calenco-Choukroun, G. (209)
267) Peptidase inhibitors
CCK-8 (cholecystokinin octapeptide); CCK, receptors; Binding in
8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) vivo; CCK receptor agonists; CCK receptor antagonists; [>H]pBC
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, 264; (Mouse) (Durieux, C. (209) 185)
serotonin); 5-HT,, receptors; Mg?*; TFMPP (trifluoromethylphen-
ylpiperazine) (Darrow, E. (209) 19) Phencyclidine (PCP)
o Receptors; DTG (1,3-di(2-tolyl guanidine); SK&F 10047 (Dumont,
Omeprazole M. (209) 245)
Gastrin; Food intake; (Chicken) (Campbell, B.J. (209) 231)
Phosphodiesterase inhibitors
Opiates Pancreas (dog); Exocrine secretion; Rolipram (Iwatsuki, K. (209) 63)
[7HIDAGO binding; Development; Hypothalamus (HammerJ,r. ,
R.P. (209) 253) Physostigmine
ATP; Cerebral vasodilatation; (Mode of action); (Rabbit) (Molnar, L.
(209) 81)
5-Opioid receptor agonists (selective)
u-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxy-
Plasma protein extravasation
dopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens;
(+ )-CP-96,345; Neurogenic inflammation; Tachykinin NK, recep-
Locomotor activity (Calenco-Choukroun, G. (209) 267)
tors (Eglezos, A. (209) 277)
p-Opioid receptor agonists (selective)
Polyamine
5-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxy-
NMDA (N-methyl-D-aspartate); Neurotoxicity; a-Difluoromethy-
dopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens;
lornithine; Ornithine decarboxylase; Neuroprotection (Kish, $.J. (209)
Locomotor activity (Calenco-Choukroun, G. (209) 267)
101)
5-Opioid receptors Postural asymmetry
Deltorphins; Locomotor activity; Social behaviour; Analgesia; (Rat) Dopamine uptake; Striatum; Basal ganglia; Nomifensine; GBR 12909;
(Negri, L. (209) 163) Amphetamine (Meloni, R. (209) 113)
Ornithine decarboxylase Prostaglandin
Polyamine; NMDA (N-methyl-D-aspartate); Neurotoxicity; a-Dif- K* channel opener; NIP-121; Cromakalim; Glibenclamide; Trachea
luoromethylornithine; Neuroprotection (Kish, S.J. (209) 101) (isolated, guinea-pig) (Shikada, K.-i. (209) 69)
Osmolarity Prostaglandin E,
Atrium (rat); ANP release; Ca** influence; V, receptor antagonists Indomethacin; Gastric acid secretion; Vagus; Baclofen (Saperas, E.
(Zongazo, M.A. (209) 45) (209) 1)